Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AstraZeneca - HER tomorrow in HER2+ metastatic breast cancer

Sharing HER experience: Case-based panel discussion


22 Sep 2020


AstraZeneca - HER tomorrow in HER2+ metastatic breast cancer


Erika Hamilton


E.M. Ciruelos1, F. Cardoso2, K.A. Gelmon3, E.P. Hamilton4

Author affiliations

  • 1 Medical Oncology Dept, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 2 Breast Unit, Champalimaud Foundation Cancer Center, 1400-038 - Lisbon/PT
  • 3 Medical Oncology Department, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 4 Drug Development Unit, Sarah Cannon Research Institute-Cancer Centre, 37203 - Nashville/US


Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings